Nykode Therapeutics (VACBF) announced last night that it has received notification from Genentech, a member of the Roche (RHHBY), of its ...

Roche’s Genentech is ending a partnership with Nykode Therapeutics that centered around a clinical-stage cancer vaccine ...

Research and development expense was $15.5 million for the third quarter of 2024, as compared to $7.6 million for the prior ...

AN orange zombie fungus that sprouts from the backs of caterpillars could be used to fight cancer, new research suggests. Scientists have found the fungus, called Cordyceps, works by stopping cell ...

Multiple clinical trial milestones were achieved, including encouraging topline data for a Phase 2 trial in CCM, the first ...

Conjunctival breach and a late onset are common in cases of endophthalmitis associated with implantation of an anti-VEGF delivery device.

Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, today announced new findings related to its ...

BlackDoctor.org spoke with neurologist and MS specialist Dr. Mitzi Williams to discuss why MS gets overlooked in the Black ...

Genentech, a member of the Roche (RHHBY), announced that it will present more than 40 abstracts across nine blood disorders at the 66th ...

Genentech to Present New and Encouraging Long-term Follow-up Data Across Broad Hematology Portfolio at ASH 2024 ...

Catch up on all the biggest pharma news to hit the industry last month, spanning from new acquisitions, insights on the NHS ...